Status:
RECRUITING
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Parti...
Eligibility Criteria
Inclusion
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
- Sodium-glucose cotransporter-2 (SGLT2) inhibitor
- Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
Exclusion
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- basal or squamous cell skin cancer
- in situ carcinomas of the cervix, or
- in situ prostate cancer
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
- amylin RA
- dual amylin and calcitonin RA
- glucagon-like peptide-1 receptor (GLP-1) RA
- glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
- GLP-1/glucagon (GCG) RAs, or
- GIP/GLP-1/GCG RAs
- Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
- Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
Key Trial Info
Start Date :
October 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07215559
Start Date
October 16 2025
End Date
May 1 2027
Last Update
December 24 2025
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona, United States, 85296
2
Central Phoenix Medical Clinic
Phoenix, Arizona, United States, 85020
3
Pima Heart
Tucson, Arizona, United States, 85741
4
SKY Clinical Research Network Group-Brown
Atlanta, Georgia, United States, 30331